NewAmsterdam Pharma Company N.V.: stockholders equity
Stockholders equity for NewAmsterdam Pharma Company N.V. Inspect selected reporting periods, original units and SEC filing links; download the financial history.
All NewAmsterdam Pharma Company N.V. financial histories
What this measure means
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
Exact concept: us-gaap:StockholdersEquity. Each value is a balance at the reporting date, not a flow earned over a year. Different units remain separate; no currency conversion or interpolation is applied.
Coverage of this history
Selected reporting periods run from 2020-12-31 to 2025-12-31. The SEC response was captured on 2026-09-21.
Selected filing history
| Period start | Period end | Value | Unit | Filed | Source filing |
|---|---|---|---|---|---|
| At date | 2025-12-31 | 683,431,000 | USD | 2026-02-18 | 10-K · 0001193125-26-056029 |
| At date | 2024-12-31 | 757,500,000 | USD | 2026-02-18 | 10-K · 0001193125-26-056029 |
| At date | 2023-12-31 | 288,393,000 | USD | 2026-02-18 | 10-K · 0001193125-26-056029 |
| At date | 2022-12-31 | 430,066,000 | USD | 2026-02-18 | 10-K · 0001193125-26-056029 |
| At date | 2021-12-31 | -113,816,000 | USD | 2025-02-26 | 10-K · 0000950170-25-027339 |
| At date | 2020-12-31 | -73,035,000 | USD | 2024-02-28 | 10-K · 0000950170-24-021668 |
Related financial histories
- NewAmsterdam Pharma Company N.V.: total assets
- NewAmsterdam Pharma Company N.V.: total liabilities
- NewAmsterdam Pharma Company N.V.: cash and cash equivalents
- NewAmsterdam Pharma Company N.V.: net income or loss
- NewAmsterdam Pharma Company N.V.: operating cash flow
- NewAmsterdam Pharma Company N.V.: contract revenue excluding tax
- NewAmsterdam Pharma Company N.V.: financing cash flow
- NewAmsterdam Pharma Company N.V.: investing cash flow
- NewAmsterdam Pharma Company N.V.: retained earnings or deficit
- NewAmsterdam Pharma Company N.V.: basic weighted-average shares
- NewAmsterdam Pharma Company N.V.: diluted weighted-average shares
- NewAmsterdam Pharma Company N.V.: basic earnings per share
- NewAmsterdam Pharma Company N.V.: diluted earnings per share
- NewAmsterdam Pharma Company N.V.: net property, plant and equipment
- NewAmsterdam Pharma Company N.V.: share-based compensation expense
- NewAmsterdam Pharma Company N.V.: operating income or loss
- NewAmsterdam Pharma Company N.V.: current assets
- NewAmsterdam Pharma Company N.V.: current liabilities
- NewAmsterdam Pharma Company N.V.: current accounts payable
- NewAmsterdam Pharma Company N.V.: operating expenses
- NewAmsterdam Pharma Company N.V.: selling, general and administrative expense
- NewAmsterdam Pharma Company N.V.: research and development expense
Inspect the source
- Entity
- NewAmsterdam Pharma Company N.V. / CIK 0001936258
- Captured
- 2026-09-21T17:36:59.418Z
- SEC response SHA-256
2065224ff325c1d6d5d97ac749f3e61e15953f1f25f26b0db8097501b804498d
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001936258.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))